(RTTNews) - Johnson & Johnson (JNJ), Thursday announced results from additional analyses of the Phase 2 DAHLIAS study, evaluating the effects of Nipocalimab in participants with primary Sjogren's ...

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

On Tuesday, Johnson & Johnson (JNJ) stock saw a decline, ending the day at $152.64 which represents a decrease of $-2.40 or -1.55% from the prior close of $155.04. The stock opened at $154.53 and ...

The first time Johnson & Johnson faced a lawsuit due to its talc-based baby powder causing cancer was way back in 1999. Since ...

HRSA’s threats of penalties led J&J to halt the plan, prompting a legal battle to protect its proposed changes. Johnson & ...

Johnson & Johnson has a high three-year median payout ratio of 71% (or a retention ratio of 29%), meaning that the company is ...

On Friday, Johnson & Johnson (JNJ) stock saw a decline, ending the day at $155.47 which represents a decrease of $-1.26 or -0.80% from the prior close of $156.73. The stock opened at $157 and touched ...

Johnson & Johnson (NYSE: JNJ) today announced results from additional analyses of the Phase 2 DAHLIAS study highlighting improvement in key measures of disease activity and significant IgG reduction ...

Johnson & Johnson (JNJ) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

In my view, such adjustments are totally acceptable, and I shared my reasons - although obviously not directly comparable - ...

Amid current economic uncertainties and market volatility, investing in defensive stocks appears as an ideal strategy for ...

With the rise of chronic diseases, technological advances and innovative drug pipelines are driving significant growth in the ...